Condorcet Global Opportunity Fund’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Condorcet Global Opportunity Fund’s Portfolio SLXP Stock Details SLXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	$4.02M	Buy	+35,000	New	+$4.24M	1.66%	17

Other funds holding SLXP

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Condorcet Global Opportunity Fund's SLXP Position: Q4 2014 in Review

Condorcet Global Opportunity Fund opened a new position in SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q4 2014: 35,000 shares worth $4.02M. The stake represents 1.66% of the portfolio and ranks #17 among its holdings.

346 funds tracked by Wall St. Rank hold SLXP as of Q4 2014.

Condorcet Global Opportunity Fund held 35,000 shares of SALIX PHARMACEUTICALS LTD DEL worth $4.02M as of Q4 2014.
SALIX PHARMACEUTICALS LTD DEL was a new Condorcet Global Opportunity Fund position in Q4 2014.
SALIX PHARMACEUTICALS LTD DEL made up 1.66% of Condorcet Global Opportunity Fund's portfolio in Q4 2014, its #17 holding.
346 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q4 2014.

Based on Condorcet Global Opportunity Fund's 13F filing for Q4 2014, filed 17 Feb 2015.